Ask your doctor today if SIMPONI ARIA® may be right for you.
SIMPONI ARIA® is a biologic infusion for the treatment of moderate to severe rheumatoid arthritis (RA) in combination with methotrexate, active psoriatic arthritis (PsA), and active ankylosing spondylitis (AS). Individual results may vary.
30-MINUTE INFUSION? LEARN MORE, RIGHT THIS WAY.
SIMPONI ARIA® (golimumab) is a biologic treatment given by intravenous infusion, also known as an IV. Your treatment starts with a 30-minute infusion, followed by a second 30-minute infusion 4 weeks later. Then you’ll receive your infusions every 8 weeks—that’s as few as 6 times a year. The infusion is given through a needle placed in your vein, usually in your arm.
RESULTS WITH SIMPONI ARIA®
Please select a condition to learn more about SIMPONI ARIA® results in medical studies.
In a medical study, 59% of RA patients treated with SIMPONI ARIA® in combination with methotrexate (MTX) had a 20% improvement in symptoms of RA (joint pain, stiffness, and swelling) at 14 weeks, compared to 25% of patients treated with MTX alone.
71% of patients treated with SIMPONI ARIA® in combination with methotrexate had no further joint damage as seen on X-ray at 24 weeks (compared to 57% of patients taking methotrexate alone).
In a medical study, 75% of patients treated with SIMPONI ARIA® had a 20% improvement in symptoms of PsA (joint pain, stiffness, and swelling) at 14 weeks, compared to 22% of patients treated with placebo.
72% of patients treated with SIMPONI ARIA® had no further joint damage as seen on X-ray at 24 weeks (compared to 43% of patients treated with placebo).
59% of patients treated with SIMPONI ARIA® noticed 75% improvement in skin symptoms of PsA (plaque thickness, redness, and scaling) at 14 weeks, compared to 14% of patients treated with placebo. SIMPONI ARIA® has not been studied in and is not approved for plaque psoriasis.
In a medical study, SIMPONI ARIA® was proven to reduce the symptoms of active AS, including back pain and morning stiffness. 73% of patients treated with SIMPONI ARIA® noticed a 20% improvement at 16 weeks, compared to 26% of patients treated with placebo.
Individual results may vary.
SERIOUS AND COMMON SIDE EFFECTS WITH SIMPONI ARIA®
Serious side effects
SIMPONI ARIA® (golimumab) can lower your ability to fight infections. Serious and sometimes fatal events may occur. There have been reports of serious infections including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that have spread throughout the body. Other possible serious side effects may include lymphoma, a rare and fatal cancer called hepatosplenic T-cell lymphoma, skin cancer, other cancers, hepatitis B, heart failure, nervous system problems, lupus-like symptoms, or allergic reactions.
Common side effects
The most common side effects of SIMPONI ARIA® include:
- upper respiratory infection (runny nose, sore throat, and hoarseness or laryngitis)
- abnormal liver tests
- decreased blood cells that fight infection
- viral infections, such as flu and cold sores in the mouth
- high blood pressure
DISCUSSING SIMPONI ARIA® WITH YOUR DOCTOR
The only way to find out if SIMPONI ARIA® is right for you is to have an open and honest conversation with your doctor about the symptoms you’re experiencing.